SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing sustained momentum driven by a growing community focused on celebrating cannabis culture and the plant's medicinal potential. Enthusiasts are actively coordinating to build a long-term presence on-chain, emphasizing the project's steady progress and the anticipation surrounding the annual 4/20 cultural milestones.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders speculate on its potential for human identity verification and its role in an increasingly AI-driven digital economy. The conversation is heavily centered on its utility as a 'Proof of Personhood' solution and the impact of recent treasury initiatives and institutional interest surrounding the project.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining strong traction as a key infrastructure player in the DeFi and Real World Asset (RWA) sectors, fueled by its ability to provide institutional-grade, real-time financial data to numerous blockchains. The community is particularly focused on its revenue-sharing model through token buybacks and the network's significant institutional backing, including collaborations with government entities for on-chain economic data.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network (MASK) is gaining attention as traders monitor its post-reverse-split price action and low float status, leading to heightened community speculation about its potential for volatility. While some participants are wary of dilution risks and choppy market conditions, others are actively tracking technical support levels and volume shifts to identify short-term momentum opportunities.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as the broader market grapples with extreme volatility driven by the escalating conflict in Iran, which has sparked fears over oil supply and global shipping routes. Investors are closely monitoring erratic signals from the Trump administration regarding the conflict and energy supply, while debating the long-term economic impacts of rising inflation and geopolitical instability.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP is currently trending as investors seek protection against rising inflation, with market participants actively debating the effectiveness of short-term TIPS ETFs as a hedge against economic volatility. Community discussions center on the interplay between persistent inflationary pressures and the broader bond market, as investors look for ways to safeguard purchasing power amidst shifting economic conditions.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing heavy selling pressure amid a broader market downturn, with community sentiment deeply polarized between long-term holders accumulating at lower levels and frustrated investors viewing the project as stagnant or a potential scam. While some proponents emphasize the project's long-term utility, development of the mainnet, and institutional validation via index inclusion as reasons to stay positioned for the 2026 cycle, others are vocal about their disappointment in the lack of sustained price appreciation and perceived leadership transparency.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is trending as the community debates its aggressive growth strategy, centered on the Tinman AI platform and recent partnerships, despite ongoing volatility and intense short interest. Investors are closely monitoring potential catalysts like new enterprise deals and regulatory tailwinds, while the community remains sharply divided over the stock's future performance and its high-profile promotional history.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending as investors weigh the impact of multiple new spot ETF launches against a broader market pullback that has pushed the token below key support levels. While retail sentiment remains polarized, the community is actively debating the token's long-term utility in global payment systems versus concerns over potential supply dilution and historical price volatility.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense community skepticism and frustration as shareholders struggle with significant underperformance and lack of management communication despite its ongoing transition into AI-focused data center infrastructure. The stock remains heavily scrutinized for its high volatility and strong correlation to Bitcoin price swings, with investors actively debating the potential impact of pending operational milestones like the Helios data center capacity and the company's delisting from the TSX.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part.</li><li>CEO George Lasezkay said that the company has “attractive assets,” including its SCS Injection Platform.&nbsp;</li><li>The company has also filed several motions to enable normal operations during the process, it said.&nbsp; &nbsp;</li></ul>Clearside Biomedical, Inc. (CLSD) said on Monday that it has filed a voluntary petition for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.Shares of the company traded nearly 69% lower at the time of writing.<h2 class="st-heading-2">What Does The Company Intend?</h2>The biopharmaceutical company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/24/3193383/0/en/Clearside-Biomedical-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process.html">seeking</a> authorization to pursue an auction and sale process. If the proposed bidding process is approved, interested parties can submit binding offers to acquire Clearside’s assets in whole or in part."Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders,” said CEO George Lasezkay.Lasezkay also added that the company has “attractive assets,” including its SCS Injection Platform, which is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.The company’s CLS-AX clinical development program is also up for sale. CLS-AX is being developed for the treatment of serious back-of-the-eye diseases, including neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy.The company has also filed several motions to enable normal operations during the process, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CLSD jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/60;" src="data:image/png;base64,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" width="587" height="60" alt="CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits"><figcaption>CLSD’s Sentiment Meter and Message Volume as of 11:21 a.m. ET on Nov. 24, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CLSD">CLSD stock</a> is down by 94% this year and by about 95% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-soars-on-reports-of-two-year-obamacare-subsidy-extension/cL5bB5mREQ7">Oscar Health Stock Soars On Reports Of Two-Year Obamacare Subsidy Extension</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, the Clearside Biomedical logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CLSD Stock Plummets After Company Files For Bankruptcy Protection

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.

Equity

The biopharmaceutical company is seeking authorization to pursue an auction and sale process.


Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of -70.15% and -23.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -4.86% and -18.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -5.26% and +15.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -14.29% and -76.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.60	--	--	N/A
Q3 '25	-$17.10	--	--	N/A
Q2 '25	-$0.09	-$0.90	-884.37%	MISSED
Q1 '25	-$0.11	-$0.11	-1.85%	MISSED
Q4 '24	-$0.10	-$0.10	-2.46%	MISSED

CLSD
Clearside Biomedical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest CLSD News

CLSDClearside Biomedical Inc